Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phas...
Carl Zeiss Meditec AG Completed Acquisition of Dutch Ophthalmic Research Center (D.O.R.C); Companies Unite to Shape Ophthalmology Market On April 04, 2024, Carl Zeiss Meditec AG announced that it acquired D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. T...
Find More
Enhertu Receives US Approval as First HER2-focused Treatment for Metastatic Solid Tumors, Independent of Tumor Origin AstraZeneca and Daiichi Sankyo's drug Enhertu (trastuzumab deruxtecan) has gained approval in the United States for treating adult patients with inoperable or metastatic HER2-positive (IHC 3+) so...
Find More
Voydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults dia...
Find More
TELA Bio Launched FDA-approved Hernia Mesh Fixation Devices On March 21, 2024, TELA Bio, Inc., a medical technology firm, launched its FDA-approved LIQUIFIX devices for hernia repairs in the United States. The LIQUIFIX FIX8™ and LIQUIFIX Precision™ are specifically engineered for laparoscopic and open femo...
Find More
Regeneron Updates Progress on Biologics License Application for Odronextamab Regeneron Pharmaceuticals, Inc. has announced that the FDA has issued Complete Response Letters (CRLs) regarding the Biologics License Application (BLA) for odronextamab in cases of relapsed/refractory (R/R) follicular lymphoma (FL) and...
Find More
Giant-cell arteritis (GCA), alternatively referred to as temporal arteritis, is a form of vasculitis primarily impacting arteries, particularly those in proximity to the temples. If left untreated, it may result in notable complications such as loss of vision. Diagnosis of the disease is often complicated by its pr...
Find More
China has become the first nation to approve Roche’s crovalimab, a paroxysmal nocturnal hemoglobinuria (PNH) treatment. Unlike AstraZeneca’s infused treatments Soliris and Ultomiris, crovalimab is administered subcutaneously. Developed by Roche’s subsidiary Chugai Pharmaceutical, crovalimab is a humanized complemen...
Find More
GSK Receives FDA Fast Track Designation for Bepirovirsen in Chronic Hepatitis B GSK plc has revealed that the US Food and Drug Administration (FDA) has awarded Fast Track status to bepirovirsen, an experimental antisense oligonucleotide (ASO) designed to treat chronic hepatitis B (CHB). Fast Track designation ai...
Find More
J&J’s Cerenovus Launched Next-Gen Stroke Revascularization Catheter On February 7, 2024, Johnson & Johnson MedTech’s Cerenovus announced the launch of its next-generation CereGlide 71 intermediate catheter with TruCourse indicated for the revascularization of patients suffering from acute ischemic stroke...
Find More
Crohn's disease (CD) is a type of inflammatory bowel disease (IBD). In this condition, the immune sy.....
Find More
Real-world evidence (RWE) is used in an exponential way to guide payment decisions and access system.....
Find More
Healthcare Performance Improvement provides proven methods for sustaining and building a culture of .....
Find More
Myasthenia Gravis is a chronic autoimmune neuromuscular disease responsible for weakness in the skel.....
Find More
Xerostomia is a condition characterized by dry mouth, which is a result of a reduced or absent flow .....
Find More
A degenerative disease, Exocrine Pancreatic Insufficiency (EPI), is a consequence of insufficient pr.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
